Dexcom (DXCM) Net Income towards Common Stockholders (2010 - 2026)

Dexcom (DXCM) has 17 years of Net Income towards Common Stockholders data on file, last reported at $199.5 million in Q1 2026.

• Net Income towards Common Stockholders for Q1 2026 came in at $199.5 million, up 89.28% year-over-year; the trailing twelve-month figure through Mar 2026 was $930.4 million (up 73.84% YoY), and the FY2025 annual result was $836.3 million, up 45.14% from the prior year.
• Net Income towards Common Stockholders slipped to $199.5 million in Q1 2026 per DXCM's latest filing, from $267.3 million in the prior quarter.
• Over five years, Net Income towards Common Stockholders peaked at $283.8 million in Q3 2025 and troughed at $48.6 million in Q1 2023.
• A 5-year average of $146.7 million and a median of $134.6 million in 2024 frame the typical range for Net Income towards Common Stockholders.
• The sharpest annual moves came in 2022 and 2023: Net Income towards Common Stockholders jumped 1832.08% in 2022, then slumped 50.05% in 2023.
• A 5-year view of Net Income towards Common Stockholders shows it stood at $91.8 million in 2022, then surged by 179.19% to $256.3 million in 2023, then slumped by 40.81% to $151.7 million in 2024, then jumped by 76.2% to $267.3 million in 2025, then retreated by 25.36% to $199.5 million in 2026.
• Business Quant data shows DXCM's Net Income towards Common Stockholders at $199.5 million in Q1 2026, $267.3 million in Q4 2025, and $283.8 million in Q3 2025.